Publications by authors named "A P Porsteinsson"
Objectives: Among participants with Alzheimer's disease (AD) we estimated the minimal clinically important difference (MCID) in apathy symptom severity on three scales.
Design: Retrospective anchor- and distribution-based analyses of change in apathy symptom scores.
Setting: Apathy in Dementia Methylphenidate Trial (ADMET) and ADMET 2 randomized controlled trials conducted at three and ten clinics specialized in dementia care in United States and Canada, respectively.
Article Synopsis
- The APOLLOE4 trial is a Phase 3 study evaluating the safety and efficacy of the oral drug ALZ-801 in patients with early Alzheimer's disease (AD) who possess the high-risk apolipoprotein E ε4/ε4 genotype.
- It enrolled 325 subjects aged 50-80, primarily with mild cognitive impairment, and aims to show a significant difference in cognitive function compared to a placebo over 78 weeks.
- Expected topline results in 2024 could provide insights into ALZ-801 as a potential first effective treatment for this high-risk group.
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS.
View Article and Find Full Text PDFObjectives: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.
Methods: The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months.
Article Synopsis
- Researchers are creating hindbrain organoids from human-induced pluripotent stem cells (iPSCs) to explore how these systems behave in different patients, helping to examine disease progression and treatment responses.
- Using iPSCs derived from healthy individuals and AD patients, they confirmed the presence of serotonergic neurons and found that different organoids showed variable reactions to the antidepressant escitalopram, indicating potential for personalized treatment approaches.